BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open. Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-po ...

Core Viewpoint - Gain Therapeutics, Inc. is advancing the discovery and development of next-generation allosteric small molecule therapies, with a focus on treating neurodegenerative diseases, rare genetic disorders, and oncology [3][5]. Company Update - The interim-CEO and current CFO Gene Mack will host a business and corporate update call on July 1, 2024, at 8:30 am ET [1]. - Participants can access the call through the company's website, and a recorded version will be available within 24 hours after the event [2]. Drug Discovery Platform - Gain Therapeutics utilizes its Magellan™ drug discovery platform, which employs AI-supported structural biology and supercomputer-powered models to identify novel allosteric binding sites on proteins [6]. - The platform can explore vast chemical spaces of over five trillion compounds to find suitable small molecule hits for experimental validation [6]. Lead Drug Candidate - Gain's lead drug candidate, GT-02287, is currently being evaluated in a Phase 1 clinical trial for the treatment of Parkinson's disease [5].

Mr. Mack is the Company's Current CFO "On behalf of Gain, I would like to thank Matthias for his significant contribution to the development of our company, as we advanced our lead candidate, GT-02287, into clinical development. Matthias played an instrumental role building the preclinical dossier for GT-02287 including the most recent positive data presented this week at FENS Forum 2024, in which administration of GT-02287 was associated with significant improvement in cognitive performance and other relat ...

Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the ...

Core Insights - Gain Therapeutics, Inc. presented a poster at the FENS Forum 2024, highlighting the positive effects of GT-02287 on cognitive performance and daily living activities in a mouse model of GBA1 Parkinson's disease [15][1][3] Group 1: Company Overview - Gain Therapeutics is a clinical-stage biotechnology company focused on discovering and developing next-generation allosteric small molecule therapies [19] - The company's lead drug candidate, GT-02287, is designed to treat GBA1 Parkinson's disease and is currently undergoing a Phase 1 clinical trial [19][3] Group 2: Drug Development and Mechanism - GT-02287 is an orally administered small molecule that acts as an allosteric protein modulator, restoring the function of the glucocerebrosidase (GCase) enzyme, which is impaired due to GBA1 gene mutations [3][19] - In preclinical studies, GT-02287 has shown to restore GCase function, reduce aggregated α-synuclein, decrease neuroinflammation, and improve both motor function and cognitive performance [3][1] Group 3: Research Findings - The study demonstrated that GT-02287 improved nest-building and motor performance in a GBA1-PD mouse model, indicating its potential to enhance complex behaviors related to cognitive function [1][3] - Biomarker changes, including reduced plasma neurofilament light chain (NfL) levels, were observed, supporting the drug's efficacy in neurodegeneration [3][1] Group 4: Future Directions - The company aims to evaluate GT-02287 in patients suffering from GBA1 Parkinson's disease, emphasizing the need for effective treatments for this chronic condition [8][15] - Gain Therapeutics is committed to engaging with the neuroscience community to further discuss its innovative approach to treating GBA1 Parkinson's disease [8][15]

A PDF of the poster presented at the FENS Forum 2024 conference is available on the Science & Technology section of the Company's website at https://www.gaintherapeutics.com/science-and-technology/posters. Forward Looking Statements Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well "These data further confirm our conviction that GT-02287 can slow or st ...

About Gain Therapeutics, Inc. Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-powered physics-based models, the company's Magellan™ drug discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of over five ...

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024. Time: 7:00am E ...

Gain Therapeutics (NASDAQ:GANX) stock is falling on Friday following the pricing of its shares in a public offering. Gain Therapeutics is also offering underwriters the option of acquiring another 1,222,222 shares in this public offering. Titan Partners Group is acting as the sole bookrunner for this offering. With this public offering, Gain Therapeutics is increasing the total number of outstanding shares. Doing so dilutes the stakes of current investors in the biotechnology company. That's one reason why ...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ("Gain" or the "Company") (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issu ...